BR112017020539B8 - Reagente para imunoensaio compreendendo um polipeptídeo, métodos de detecção de anticorpos e/ou antígenos para o vírus da hepatite c em uma amostra biológica, de seleção de amostras biológicas de um suprimento de amostras biológicas humanas, bem como polipeptídeo isolado e kit para teste imunodiagnóstico - Google Patents

Reagente para imunoensaio compreendendo um polipeptídeo, métodos de detecção de anticorpos e/ou antígenos para o vírus da hepatite c em uma amostra biológica, de seleção de amostras biológicas de um suprimento de amostras biológicas humanas, bem como polipeptídeo isolado e kit para teste imunodiagnóstico

Info

Publication number
BR112017020539B8
BR112017020539B8 BR112017020539A BR112017020539A BR112017020539B8 BR 112017020539 B8 BR112017020539 B8 BR 112017020539B8 BR 112017020539 A BR112017020539 A BR 112017020539A BR 112017020539 A BR112017020539 A BR 112017020539A BR 112017020539 B8 BR112017020539 B8 BR 112017020539B8
Authority
BR
Brazil
Prior art keywords
biological samples
polypeptide
hepatitis
virus
immunoassay
Prior art date
Application number
BR112017020539A
Other languages
English (en)
Other versions
BR112017020539B1 (pt
BR112017020539A2 (pt
Inventor
Alexander Gyenes
Angelica Medina-Selby
Y Chien David
Guenzi Coit Doris
Jian Zheng
Andrew Hall John
Toshiya Fujihara
Original Assignee
Grifols Worldwide Operations Ltd
Ortho Clinical Diagnostics K K
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd, Ortho Clinical Diagnostics K K, Ortho Clinical Diagnostics Inc filed Critical Grifols Worldwide Operations Ltd
Publication of BR112017020539A2 publication Critical patent/BR112017020539A2/pt
Publication of BR112017020539B1 publication Critical patent/BR112017020539B1/pt
Publication of BR112017020539B8 publication Critical patent/BR112017020539B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

polipeptídeos ns3 modificados/ns4a de hcv e usos dos mesmos. são descritos polipeptídeos modificados do vírus da hepatite c. os polipeptídeos incluem o domínio ns4a do hcv e o domínio ns3 modificado de hcv. os polipeptídeos retêm os epítopos conformacionais. também são descritos imunoensaios para hcv que incluem os polipeptídeos.
BR112017020539A 2015-03-27 2015-06-22 Reagente para imunoensaio compreendendo um polipeptídeo, métodos de detecção de anticorpos e/ou antígenos para o vírus da hepatite c em uma amostra biológica, de seleção de amostras biológicas de um suprimento de amostras biológicas humanas, bem como polipeptídeo isolado e kit para teste imunodiagnóstico BR112017020539B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139183P 2015-03-27 2015-03-27
US62/139,183 2015-03-27
PCT/US2015/036941 WO2016160046A1 (en) 2015-03-27 2015-06-22 Hcv ns4a/modified ns3 polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
BR112017020539A2 BR112017020539A2 (pt) 2018-07-10
BR112017020539B1 BR112017020539B1 (pt) 2023-12-12
BR112017020539B8 true BR112017020539B8 (pt) 2024-01-09

Family

ID=57004859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020539A BR112017020539B8 (pt) 2015-03-27 2015-06-22 Reagente para imunoensaio compreendendo um polipeptídeo, métodos de detecção de anticorpos e/ou antígenos para o vírus da hepatite c em uma amostra biológica, de seleção de amostras biológicas de um suprimento de amostras biológicas humanas, bem como polipeptídeo isolado e kit para teste imunodiagnóstico

Country Status (10)

Country Link
US (2) US10267803B2 (pt)
EP (1) EP3274478B1 (pt)
JP (2) JP6859314B2 (pt)
CN (1) CN107735499B (pt)
BR (1) BR112017020539B8 (pt)
CA (1) CA2980718C (pt)
DK (1) DK3274478T3 (pt)
ES (1) ES2832335T3 (pt)
RU (1) RU2017133463A (pt)
WO (1) WO2016160046A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3274478T3 (da) * 2015-03-27 2020-11-23 Ortho Clinical Diagnostics K K Hcv-ns4a/modificerede ns3-polypeptider og anvendelser deraf
WO2020205510A1 (en) * 2019-03-29 2020-10-08 Trustees Of Boston University Chimeric antigen receptor (car) modulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3886363T3 (de) 1987-11-18 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville NANBV-Diagnostika
US5256532A (en) 1988-05-02 1993-10-26 Zynaxis Technologies, Inc. Methods, reagents and test kits for determination of subpopulations of biological entities
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
DE69232871T2 (de) 1991-06-24 2003-05-08 Chiron Corp Polypeptide des hepatitis c-virus (hiv)
UA39944C2 (uk) 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
ATE551423T1 (de) * 1993-04-27 2012-04-15 Innogenetics Nv Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika
JP3217600B2 (ja) 1994-07-12 2001-10-09 株式会社先端生命科学研究所 非ａ非ｂ型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ
CA2250723C (en) 1996-05-24 2012-07-17 Chiron Corporation Multiple epitope fusion protein
WO1999028482A2 (en) * 1997-11-28 1999-06-10 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
JP2002534084A (ja) * 1999-01-08 2002-10-15 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスｎｓ３プロテアーゼの修飾形
BRPI0111682B8 (pt) 2000-06-15 2021-07-27 Chiron Corp suporte sólido de imunoensaio, kit de teste de imunodiagnóstico, métodos de produção de um suporte sólido de imunoensaio, e de detecção de infecção pelo vírus da hepatite c (hcv) em uma amostra biológica, e, uso de um suporte sólido de imunoensaio
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
EP1539809A4 (en) * 2002-07-02 2006-03-08 Chiron Corp HCV fusion proteins with modified NS3 domains
EP1802778B1 (en) * 2004-08-27 2011-10-05 Novartis Vaccines and Diagnostics, Inc. Hcv multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof
ES2387321T3 (es) * 2006-03-09 2012-09-20 Transgene Sa Proteína de fusión no estructural del virus de la hepatitis C
US20100297607A1 (en) * 2009-05-20 2010-11-25 Jian Zheng Reagents For HCV Antigen-Antibody Combination Assays
WO2014093602A1 (en) * 2012-12-14 2014-06-19 Profectus Biosciences, Inc. Compositions and methods for treating and preventing hepatitis c virus infection
DK3274478T3 (da) * 2015-03-27 2020-11-23 Ortho Clinical Diagnostics K K Hcv-ns4a/modificerede ns3-polypeptider og anvendelser deraf

Also Published As

Publication number Publication date
JP2020129001A (ja) 2020-08-27
RU2017133463A3 (pt) 2019-04-29
JP2018513390A (ja) 2018-05-24
US10753939B2 (en) 2020-08-25
DK3274478T3 (da) 2020-11-23
CA2980718A1 (en) 2016-10-06
ES2832335T3 (es) 2021-06-10
US20180011096A1 (en) 2018-01-11
US10267803B2 (en) 2019-04-23
ES2832335T8 (es) 2021-06-23
CN107735499B (zh) 2022-05-03
BR112017020539B1 (pt) 2023-12-12
CA2980718C (en) 2021-06-01
JP6859314B2 (ja) 2021-04-14
BR112017020539A2 (pt) 2018-07-10
US20190271700A1 (en) 2019-09-05
EP3274478A1 (en) 2018-01-31
EP3274478B1 (en) 2020-09-23
CN107735499A (zh) 2018-02-23
RU2017133463A (ru) 2019-04-29
EP3274478A4 (en) 2018-08-08
WO2016160046A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
BR112018016337A2 (pt) anticorpos monoclonais da proteína ns1 de vírus antidengue
TR201900160T4 (tr) Bir anti-ilaç antikoru varlığının veya miktarının saptanmasına yönelik analizler.
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
PH12018502389A1 (en) Immunochromatography analysis device for detecting zika virus
BR112015023355A2 (pt) antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
MX2019001767A (es) Anticuerpos monoclonales que se unen al dominio de union a lipidos de la proteina de la capside del virus de la hepatitis c (vhc).
BR112015008036A2 (pt) população de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica e kit
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
CO2019008675A2 (es) Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
BR112017011545A2 (pt) ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente
WO2015196192A3 (en) Methods and compositions relating to dengue virus
CY1125342T1 (el) Μεθοδοι για την ανιχνευση και/ή μετρηση αντισωματων εναντι των αντισωματων φαρμακου, ιδιως αντισωματων εναντι των αντισωματων φαρμακου προκυπτοντων κατα τη θεραπευτικη αγωγη
AR105379A1 (es) Dispositivo para detectar proteínas mal plegadas y sus métodos de uso
BR112017020539B8 (pt) Reagente para imunoensaio compreendendo um polipeptídeo, métodos de detecção de anticorpos e/ou antígenos para o vírus da hepatite c em uma amostra biológica, de seleção de amostras biológicas de um suprimento de amostras biológicas humanas, bem como polipeptídeo isolado e kit para teste imunodiagnóstico
GB2522131A (en) Isotopic labelling of proteins
WO2014126487A3 (en) Diagnosis and detection of dengue virus infection using chicken egg antibodies
BR112017006569A2 (pt) composição, método para produzir uma composição, método para detectar anticorpos, uso de uma composição e kit de reagentes para a detecção de anticorpos
WO2016069762A3 (en) Subject anti-hcv antibody detection assays employing ns3 capture peptides
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus
MX2018015047A (es) Metodo para la deteccion de un anticuerpo igm especifico para un flavivirus en una muestra.
BR112018072042A2 (pt) métodos de detecção de polipeptídeo e de processamento prévio de amostras, reagente de processamento prévio, kit de detecção de hcv e uso de composição
DE602005014659D1 (de) Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/06/2015, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2762 DE 12/12/2023, QUANTO AO ITEM (73) NOME DO TITULAR E ITEM (73) ENDERECO DO TITULAR.